Alimera Sciences (ALIM) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALIM shares.
View ALIM analyst ratings or view top-rated stocks.

2 equities research analysts have issued 12-month target prices for Alimera Sciences' shares. Their ALIM share price forecasts range from $4.50 to $8.00. On average, they anticipate the company's share price to reach $5.83 in the next twelve months. This suggests a possible upside of 81.7% from the stock's current price.
View analysts price targets for ALIM or view top-rated stocks among Wall Street analysts.

Alimera Sciences' stock was trading at $2.71 at the beginning of 2023. Since then, ALIM stock has increased by 18.5% and is now trading at $3.21.
View the best growth stocks for 2023 here.

Alimera Sciences saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 121,700 shares, a drop of 82.5% from the August 15th total of 697,400 shares. Based on an average daily trading volume, of 43,000 shares, the short-interest ratio is presently 2.8 days. Currently, 3.1% of the shares of the stock are sold short.
View Alimera Sciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ALIM earnings forecast.

Alimera Sciences, Inc. (NASDAQ:ALIM) issued its quarterly earnings results on Thursday, August, 10th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of $0.06 by $0.50. The biopharmaceutical company had revenue of $17.54 million for the quarter, compared to analysts' expectations of $20.36 million.

Alimera Sciences's stock reverse split before market open on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB).

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

Alimera Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Velan Capital Investment Management LP (18.84%), Renaissance Technologies LLC (1.47%), Geode Capital Management LLC (0.67%), Osaic Holdings Inc. (0.13%), Osaic Holdings Inc. (0.13%) and Perritt Capital Management Inc. (0.11%). Insiders that own company stock include Adam Morgan, Alto Investors Lp Palo, Caligan Partners Lp, James R Largent, John Philip Jones, Philip Ashman, Richard S Eiswirth Jr and Stanley Morgan.
View institutional ownership trends.

Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALIM stock can currently be purchased for approximately $3.21.

Alimera Sciences (NASDAQ:ALIM) has a market capitalization of $28.25 million and generates $54.13 million in revenue each year. The biopharmaceutical company earns $-18,110,000.00 in net income (profit) each year or ($3.32) on an earnings per share basis.

The company employs 150 workers across the globe.

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The official website for the company is www.alimerasciences.com. The biopharmaceutical company can be reached via phone at (678) 990-5740, via email at scottg@coreir.com, or via fax at 678-990-5744.